Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”

Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

Subjects:

The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. by Shuhuan Zhang (748003)

Table of step height. by Jianbo Jia (717814)

“…Finally, by making corresponding test blocks, it was found that the peak value of forward resistance when the 10.5°test block crossed the steps of 1mm, 2mm and 3mm height decreased by 19.8%, 25.0% and 13.9% respectively, and the mean value decreased by 30.8%, 27.2% and 24.1% respectively, which was close to the simulation results, and verified the accuracy of the finite element analysis results.…”

The well wall step. by Jianbo Jia (717814)

“…Finally, by making corresponding test blocks, it was found that the peak value of forward resistance when the 10.5°test block crossed the steps of 1mm, 2mm and 3mm height decreased by 19.8%, 25.0% and 13.9% respectively, and the mean value decreased by 30.8%, 27.2% and 24.1% respectively, which was close to the simulation results, and verified the accuracy of the finite element analysis results.…”

Knockdown of ATP2C1 results in a minor decrease of [Ca²⁺] in WPB. by Julian Terglane (12975565)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. by Zahra Hosseininia (22265113)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Lens profiles as Ez (orange lines) force was increased and Az and Pz (green lines) forces were decreased. by Ronald A. Schachar (16674576)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection. by Penghui Hu (695020)

Wnt signaling decreases the recruitment of RAB8a to basal bodies. by Cheng Yuan (160315)